Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.25 GBX | 0.00% | 0.00% | -39.34% |
05/04 | SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie | MT |
22/03 | SkinBioTherapeutics half-year revenue jumps on UK-based sales | AN |
Sales 2024 * | 1.1M 1.38M 115M | Sales 2025 * | - | Capitalization | 17.83M 22.38M 1.87B |
---|---|---|---|---|---|
Net income 2024 * | -2M -2.51M -209M | Net income 2025 * | - | EV / Sales 2024 * | 16.8 x |
Net Debt 2024 * | 600K 753K 62.76M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.17
x | P/E ratio 2025 * |
-
| Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.98% |
Current month | -27.45% | ||
1 month | -22.11% | ||
3 months | -16.85% | ||
6 months | -68.10% | ||
Current year | -39.34% |
Managers | Title | Age | Since |
---|---|---|---|
Stuart Ashman
CEO | Chief Executive Officer | - | 18/19/18 |
Manprit Randhawa
DFI | Director of Finance/CFO | 41 | 01/22/01 |
Stephen France
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 01/17/01 | |
Martin Hunt
CHM | Chairman | 66 | 03/16/03 |
Stuart Ashman
CEO | Chief Executive Officer | - | 18/19/18 |
Date | Price | Change | Volume |
---|---|---|---|
02/24/02 | 9.25 | 0.00% | 236,233 |
01/24/01 | 9.25 | +1.20% | 1,064,455 |
30/24/30 | 9.14 | -1.19% | 142,806 |
29/24/29 | 9.25 | 0.00% | 127,560 |
26/24/26 | 9.25 | 0.00% | 206,658 |
Delayed Quote London S.E., May 02, 2024 at 09:05 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.34% | 22.28M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- SBTX Stock